The adequacy of hemodialysis is now assessed by measuring the removal of the single solute urea. Other solutes however likely contribute more than urea to the residual uremic illness suffered by hemodialysis patients. We here review methods which could be employed to increase the clearance of non-urea solutes. New clinical studies will be required to test the extent to which increasing the clearance on non-urea solutes with these various characteristics can improve patients' health.  

This session will review recent implementation efforts that integrate the kidney failure risk equation in electronic health records and laboratory information systems. We will also review new prediction models that have been developed to predict CKD progression at earlier stages of the disease, as well as solutions that implement risk prediction in the clinical workflow.  

This session offers a unique opportunity to study the impact of high doses of Kt/Vurea in one of the largest single center retrospective cohort studies of 53 children on PD using conventional PD solutions, who underwent repeated peritoneal equilibration tests every 9 months on growth and other factors. Similar to the CANUSA and ADEMEX studies in adults, excessive Kt/Vurea was not associated with better growth. Apart from age and delta BMI, there was a positive impact of growth with aggressive bicarbonate supplementation.

This session will discuss senescence or biological ageing is the gradual deterioration of functional characteristics in living organisms, along with prevalence of “burden of lifestyle” diseases accumulates with biological age. Dr. Stenvinkel will also touch on how chronic kidney disease is a clinical condition of premature ageing.

This session will aim to examine the barriers towards home dialysis adoption. Moreover, we will illustrate examples of feasible and implementable strategies which will help to enhance home dialysis adoption and quality of care.

The session gives an overview of peritonitis in PD patients as regards diagnostics and initial treatment. The epidemiology of peritonitis and comlications and quality reporting standards are reviewed. Educational case reports are described.

This talk will focus on potential novel uses for peritoneal dialysis, other than the treatment of acute or end-stage kidney diseases. Two areas will be discussed: the use of peritoneal dialysis for removal of exogenous toxins (e.g. pharmacologic agents) or endogenous toxins (e.g. ammonia) and the use of peritoneal dialysis to minimize damage in the setting of acute stroke.

Cardiac surgical procedures with cardiopulmonary support in patients on dialysis presents several challenges including acidemia, volume overload, and hyperkalemia. Different strategies are employed to safely manage these patients in the peri-operatively and careful pre-operative planning and coordination to provide pre-, intra- and post-operative renal replacement therapies for such patients is imperative. Implementing a convective ultrafiltration protocol using pre-existing connections on the cardiopulmonary bypass pump performed by the perfusion team allows for control of potassium concentration with existing personnel and minimal additional equipment.